About: Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations
Creator	Akhavan-Niaki, Haleh Hosseini, Mohammad Paniri, Alireza Rasoulinejad, Ahmad
Source	Elsevier; Medline; PMC
abstract	Antimalaria drugs such as chloroquine (CQ) and hydroxychloroquine (HCQ) have been administered to several inflammatory diseases including rheumatoid arthritis and systemic lupus erythematosus, and infectious diseases such as acquired immune deficiency syndrome and influenza. Recently, several patients infected with novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were given HCQ, and showed a discrepant response. HCQ inhibits SARS-CoV-2 cell entry, and inflammatory cascade by interfering with lysosomal and endosomal activities, and autophagy, impeding virus-membrane fusion, and inhibiting cytokine production resulted from inflammatory pathways activation. Despite ongoing administration of HCQ in a wide spectrum of disorders, there are some reports about several side effects, especially retinopathy in some patients treated with HCQ. Cytochrome P450 (CYP450) and its isoforms are the main metabolizers of HCQ and CQ. Pharmacokinetic properties of CYP enzymes are influenced by CYP polymorphism, non-coding RNAs, and epigenetic mechanisms such as DNA methylation, and histone acetylation. Accumulating evidence about side effects of HCQ in some patients raise the possibility that different response of patients to HCQ might be due to difference in their genome. Therefore, CYP450 genotyping especially for CYP2D6 might be helpful to refine HCQ dosage. Also, regular control of retina should be considered for patients under HCQ treatment. The major focus of the present review is to discuss about the pharmacokinetic and pharmacodynamic properties of CQ and HCQ that may be influenced by epigenetic mechanisms, and consequently cause several side effects especially retinopathy during SARS-CoV-2 therapy.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1016/j.ejphar.2020.173454
bibo:pmid	32763298
has license	no-cc
sha1sum (hex)	3bbf87f45c845efb02c1bc94670ce8e9dff86ef4
schema:url	https://doi.org/10.1016/j.ejphar.2020.173454
resource representing a document's title	Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations
has PubMed Central identifier	PMC7402235
has PubMed identifier	32763298
schema:publication	Eur J Pharmacol
resource representing a document's body	covid:3bbf87f45c845efb02c1bc94670ce8e9dff86ef4#body_text
is schema:about of	named entity 'European' named entity 'epigenetic' named entity 'retinopathy' named entity 'Journal' named entity 'hydroxychloroquine' named entity 'inflammatory diseases' named entity 'modulations' named entity 'hydroxychloroquine' named entity 'influenza' named entity 'HCQ' named entity 'doi' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'SARS-CoV-2' named entity 'epigenetic' named entity 'retinopathy' named entity 'retinopathy' named entity 'CYP450' named entity 'isoforms' named entity 'lysosomal' named entity 'siRNA' named entity 'antiviral' named entity 'TNF-α' named entity 'melanin' named entity 'substrates' named entity 'liver injury' named entity 'DNA methylation' named entity 'HCQ' named entity 'retinal disease' named entity 'retinopathy' named entity 'malaria' named entity 'obesity' named entity 'solid cancer' named entity 'HEK' named entity 'OATP1A2' named entity 'CYP2D6' named entity 'China' named entity 'SLE' named entity 'SARS-CoV-2' named entity 'vitamin' named entity 'HCQ' named entity 'liver' named entity 'rat' named entity 'HCQ' named entity 'macrophages' named entity 'HCQ' named entity 'volumes of distribution' named entity 'HCQ' named entity 'expression levels' named entity 'retina' named entity 'membrane fusion' named entity 'CYP450' named entity 'human immunodeficiency virus' named entity 'antigen presenting cells' named entity 'angiotensin converting enzyme' named entity 'hnRNPA2B1' named entity 'HCQ' named entity 'lipofuscin' named entity 'Kyburz' named entity 'interferon' named entity 'CYP2C8' named entity 'nasopharyngeal' named entity 'major histocompatibility complex' named entity 'organelle' named entity 'HCQ' named entity 'xenobiotic metabolism' named entity 'isomers' named entity 'CYP2B6' named entity 'SNPs' named entity '5-aza' named entity 'TLR' named entity 'HCQ' named entity 'lung' named entity 'choroid' named entity 'rough endoplasmic reticulum' named entity 'CYP1B1' named entity 'age-related macular degeneration' named entity 'early endosomes' named entity 'endosome'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software